

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
22 August 2002 (22.08.2002)

PCT

(10) International Publication Number
WO 02/064576 A1

- (51) International Patent Classification⁷: C07D 263/57, A61K 31/496, C07D 277/68, 209/42, 417/12, 241/44, 213/63, 215/20, A61P 21/00
- (74) Agent: HUGUES, Blair, A.; McDonnell Boehnen Hulbert & Berghoff, 300 S. Wacker Drive, S. 3200, Chicago, IL 60606 (US).
- (21) International Application Number: PCT/US01/51032
- (22) International Filing Date: 19 October 2001 (19.10.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/694,155 23 October 2000 (23.10.2000) US
- (71) Applicant (for all designated States except US): CV THERAPEUTICS, INC. [US/US]; 3172 Porter Drive, Palo Alto, CA 94304 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ZABLOCKI, Jeff, A. [US/US]; 580 Sleeper Ave., Mountain View, CA 94040 (US). IBRAHIM, Prabha, N. [US/US]; 3380 Lubich Dr., Mountain View, CA 94040 (US). SHENK, Kevin [US/US]; 565 Arastradero Rd., Apt. 203, Palo Alto, CA 94306 (US). ELZEIN, Eifatih [SD/US]; 4644 Creekwood Dr., Fremont, CA 94555 (US). PALLE, Venkata [IN/US]; 600 Rainbow Dr., Mountain View, CA 94041 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS



(57) Abstract: Novel compounds of the general formula (I): and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

TITLE: HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID
OXIDATION INHIBITORS

5

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is concerned with piperazine derivatives, therapeutic dosage
10 forms including one or more of the derivatives, and methods for treating diseases in
mammals, and in particular, in a human in a therapy selected from the group including
protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles
subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock
conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular
15 diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable
angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

2. Description of the Art

U.S. Patent No. 4,567,264, the specification of which is incorporated herein by
reference, discloses a class of substituted piperazine compounds that includes a compound
20 known as ranolazine, (\pm)-N- (2,6-dimethylphenyl)-4-[2-hydroxy-3- (2-methoxyphenoxy)-
propyl]-1-piperazineacetamide, and its pharmaceutically acceptable salts, and their use in the
treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced
angina, and myocardial infarction.

U.S. Patent No. 5,506,229, which is incorporated herein by reference, discloses the use
25 of ranolazine and its pharmaceutically acceptable salts and esters for the treatment of tissues
experiencing a physical or chemical insult, including cardioplegia, hypoxic or reperfusion
injury to cardiac or skeletal muscle or brain tissue, and for use in transplants. In particular,
ranolazine is particularly useful for treating arrhythmias, variant and exercise-induced angina,
and myocardial infarction by partially inhibiting cardiac fatty acid oxidation. Conventional
30 oral and parenteral ranolazine formulations are disclosed, including controlled release
formulations. In particular, Example 7D of U.S. Patent No. 5,506,229 describes a controlled
release formulation in capsule form comprising microspheres of ranolazine and
microcrystalline cellulose coated with release controlling polymers.


Despite the important discovery that ranolazine is a very useful cardiac therapeutic agent, there remains a need for compounds that are partial fatty acid oxidation inhibitors that have a half-life greater than ranolazine and that have activities as least similar to ranolazine.

SUMMARY OF THE INVENTION

5 This invention includes novel heteroaryl alkyl piperazine derivatives that are partial fatty acid oxidation inhibitors with good therapeutic half-lives.

This invention also includes novel substituted piperazine compounds that can be administered to a mammal to protect skeletal muscles against damage resulting from trauma, to protecting skeletal muscles subsequent to muscle or systemic diseases such as intermittent
10 claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, and to treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.

This invention includes a class of substituted piperazine compounds having the
15 formula:



wherein $m = 1, 2, \text{ or } 3$;

$q = \text{NH, O, or S}$;

R^1, R^2, R^3, R^4 and R^5 are each independently selected from the group consisting of
20 hydrogen, halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N(R}^{20})_2$, S(O)R^{22} , SO_2R^{22} , $\text{SO}_2\text{N(R}^{20})_2$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON(R}^{20})_2$, COR^{20} , CO_2R^{20} , $\text{CON(R}^{20})_2$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N(R}^{20})_2$, S(O)R^{22} , and SO_2R^{22} and wherein R^1 and R^2 or R^2 and R^3 or
25 R^3 and R^4 or R^4 and R^5 when taken together with the carbons to which they are attached may form a 6-membered aromatic ring that is optionally substituted by alkyl, trifluoroalkyl, alkoxy, or halogen;

R^6 , R^7 and R^8 each independently selected from the group consisting of hydrogen or C_{1-3} alkyl;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, CO_2R^{20} , $CON(R^{20})_2$, C_{1-4} alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , CN, OR^{20} , $N(R^{20})_2$, CO_2R^{20} , $CON(R^{20})_2$ or aryl, wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl or R^{11} and R^{13} or R^9 and R^{15} or R^9 and R^{11} or R^{11} and R^{15} or R^9 and R^{13} may join together to form a ring including from 1 to 3 carbon atoms;

R^{17} is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22} , $SO_2N(R^{20})_2$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, COR^{20} , CO_2R^{20} , $CON(R^{20})_2$, $NR^{20}SO_2R^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, or SO_2R^{22} ;

R^{20} is selected from the group consisting of H, C_{1-15} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl, CN, $-O-C_{1-6}$ alkyl, or CF_3 ; and

R^{22} is selected from the group consisting of C_{1-15} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, $O-C_{1-6}$ alkyl, CF_3 , or heteroaryl.

In another embodiment, this invention is a substituted piperazine compound selected from the group consisting of N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, 2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, 4-(3-{4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl}-2-hydroxy-propoxy)-1H-indole-2-carboxylic acid amide, 2-{4-[3-(benzothiazol-6-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-


propyl]-3,5-dimethyl-piperazine-1-yl} acetamide, 2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(pyridin-3-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl} acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl} acetamide, 2-{4-[3-(benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,5-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,3-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{(2R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]}(1,4-diazaperhydroepinyl)-N-(2,6-dimethylphenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-hydroxyphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-

methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(4-
 carboxamidophenyl)acetamide, 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-
 yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-hydroxy-
 3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-
 5 {4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethyl-4-
 hydroxyphenyl)acetamide, 2-{5-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-
 2,5-diazabicyclo[2.2.1]hept-2-yl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-
 (2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-sulfamoylphenyl)acetamide, 2-{(3S)-
 4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-
 10 dimethylphenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-
 yloxy)propyl]piperazinyl}-N-naphthylacetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-
 {4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl} acetamide, 2-{4-[2-
 hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-phenylacetamide, 2-{4-[2-
 hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4,5-
 15 trichlorophenyl)acetamide, 2-{4-[2-hydroxy-3-(4-methoxyphenyl)propyl]piperazinyl}-N-
 (3,4,5-trichlorophenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-
 yloxy)propyl]piperazinyl}-N-(2-chloro-4-methylphenyl)-acetamide, 2-{4-[2-hydroxy-3-(2-
 methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide, 2-{4-
 [2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,5-dichlorophenyl)-
 20 acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4-
 dichlorophenyl)-acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-
 yloxy)propyl]piperazinyl}-N-[3-methoxy-5-(trifluoromethyl)phenyl]acetamide, 2-{4-[2-
 hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[3,5-
 25 dichloro)phenyl]acetamide, and 2-{4-[2-hydroxy-3-(2-((1E)buta-1,3-dienyl)benzothiazol-5-
 yloxy)propyl]piperazinyl}-N-[4-chloro-2-methoxy-5-methylphenyl]acetamide.

In yet another embodiment, this invention is a method for administering one or more
 composition of this invention to a mammal in a treatment selected from the group consisting
 of protecting skeletal muscles against damage resulting from trauma, protecting skeletal
 muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat
 30 shock conditions, to preserve donor tissue and organs used in transplants, and to treat
 cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant)
 angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial
 infarction.

DETAILED DESCRIPTION OF THE INVENTION

A class of substituted piperazine compounds having the following formula:



wherein $m = 1, 2, \text{ or } 3$;

$q = \text{NH, O, or S}$;

- 5 R^1, R^2, R^3, R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, and SO_2R^{22} and wherein R^2 and R^3 or R^3 and R^4 or R^4 and R^5 when taken together with the carbons to which they are attached may form a 6-membered aromatic ring that is optionally substituted by alkyl, trifluoroalkyl, alkoxy, or halogen;

- 15 R^6, R^7 and R^8 each independently selected from the group consisting of hydrogen or C_{1-3} alkyl;

- 20 $R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}$ and R^{16} are each independently selected from the group consisting of hydrogen, CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, C_{1-4} alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , CN , OR^{20} , $\text{N}(\text{R}^{20})_2$, CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$ or aryl, wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl or R^{11} and R^{13} or R^9 and R^{15} or R^9 and R^{11} or R^{11} and R^{15} or R^9 and R^{13} may join together to form a ring including from 1 to 3 carbon atoms;

- 25 R^{17} is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the

group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or SO₂R²²;

R²⁰ is selected from the group consisting of H, C₁₋₁₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl, CN, -O-C₁₋₆ alkyl, or CF₃; and

- 5 R²² is selected from the group consisting of C₁₋₁₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O-C₁₋₆ alkyl, CF₃, or heteroaryl.

In a preferred embodiment, q = NH or O.

- 10 In a preferred embodiment, R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, halo, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, SO₂N(R²⁰)₂, CO₂R²⁰, CON(R²⁰)₂, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or SO₂R²². In another
- 15 preferred embodiment, R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, C₁₋₅ alkyl, C₂₋₅ alkenyl, or C₂₋₅ alkynyl, wherein the alkyl substituent is optionally substituted with CF₃. In yet another preferred embodiment, R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, or C₁₋₃ alkyl wherein the alkyl substituent is optionally substituted with CF₃.
- 20 More preferably R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, CF₃, OR²⁰, or C₁₋₂ alkyl, with hydrogen, OR²⁰, or methyl being more preferred and hydrogen or methyl being most preferred.

- In an alternative preferred embodiment, any one of R¹ and R² or R² and R³ or R³ and R⁴ or R⁴ and R⁵ when taken together with the carbons to which they are attached may form a
- 25 6-membered aromatic ring that is optionally substituted by alkyl, trifluoroalkyl, alkoxy, or halogen with the remaining substituents defined as set forth in the paragraph above. In this embodiment, it is most preferred that R² and R³ when taken together with the carbons to which they are attached form a 6-membered aromatic ring.

- In a preferred embodiment, R⁶, R⁷ and R⁸ each independently selected from the group consisting of hydrogen or C₁₋₃ alkyl and most preferably hydrogen or methyl.
- 30

In a preferred embodiment, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶ are each independently selected from the group consisting of hydrogen, CON(R²⁰)₂, C₁₋₄ alkyl, or wherein R⁹ and R¹⁰ may together form a carbonyl, or R¹¹ and R¹² may together form a

carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl. In yet another embodiment, R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen or C_{1-2} alkyl, wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl. In a more preferred embodiment, R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, or methyl, wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl. In another embodiment, R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, or C_{1-2} alkyl, wherein the alkyl substituent is optionally substituted with 1 substituent selected from the group consisting of $N(R^{20})_2$, or aryl or wherein R^9 and R^{10} may together form a carbonyl. In another preferred embodiment, R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen or C_{1-2} alkyl, or wherein R^9 and R^{10} may together form a carbonyl. In still another preferred embodiment, R^{11} and R^{15} are each selected from the group consisting of hydrogen or methyl, R^9 , R^{10} , R^{12} , R^{13} , R^{14} and R^{16} are each hydrogen and R^9 and R^{10} may together form a carbonyl. In another preferred embodiment, R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each hydrogen.

In one preferred embodiment, R^{17} is a heteroaryl that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-3} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF_3 , OR^{20} , or $N(R^{20})_2$. In another embodiment, R^{17} is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 5 heteroatoms each selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22} , $SO_2N(R^{20})_2$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, COR^{20} , CO_2R^{20} , $CON(R^{20})_2$, $NR^{20}SO_2R^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, or SO_2R^{22} . In this embodiment, R^{17} is preferably a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 3 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the

group consisting of hydrogen, halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF₃, OR²⁰, or N(R²⁰)₂. More preferably R¹⁷ is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 2 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂, C₁₋₃ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF₃, or OR²⁰. Even more preferably in this embodiment, R¹⁷ is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of indole, benzothiazole, and benzoxazole that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂, C₁₋₃ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF₃, or OR²⁰. In this preferred embodiment, R¹⁷ is preferably benzothiazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂, C₁₋₃ alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF₃. More preferably R¹⁷ is benzothiazole that is optionally substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl or phenyl. In an alternative preferred embodiment, R¹⁷ is 5-substituted benzothiazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂, C₁₋₃ alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF₃. The 5-substituted benzothiazole is preferably substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl or phenyl.

In another preferred embodiment, R¹⁷ is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 4 nitrogen atoms that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, NR²⁰CO₂R²², NR²⁰CON(R²⁰)₂, COR²⁰, CO₂R²⁰, CON(R²⁰)₂, NR²⁰SO₂R²², C₁₋₁₅ alkyl, C₂₋₁₅ alkenyl, C₂₋₁₅ alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂,

$S(O)R^{22}$, or SO_2R^{22} . More preferably, R^{17} is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 3 nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF_3 , OR^{20} , or $N(R^{20})_2$. Most preferably, R^{17} is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl;

In yet another preferred embodiment, R^{17} is a 5 or 6-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, S, or O that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22} , $SO_2N(R^{20})_2$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, COR^{20} , CO_2R^{20} , $CON(R^{20})_2$, $NR^{20}SO_2R^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, or SO_2R^{22} . More preferably, R^{17} is a 5 or 6 membered ring including from 1 to 3 heteroatoms selected from N, S, or O nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF_3 , OR^{20} , or $N(R^{20})_2$. Even more preferably, R^{17} is a 6 membered ring including from 1 to 2 nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF_3 , OR^{20} , or $N(R^{20})_2$. Most preferably in this embodiment, R^{17} is a 6 membered ring containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl.

In yet still another preferred embodiment, R^{17} is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of benzothiazole, and benzoxazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, CF_3 , OR^{20} , C_{1-3} alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF_3 and preferably

optionally substituted with methyl.

In a preferred embodiment, R²⁰ is selected from the group consisting of H, C₁₋₁₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkylcyano, -O-C₁₋₆ alkyl, or CF₃. R²⁰ is selected from the group consisting of H, C₁₋₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, -OMe, or CF₃. In a more preferred embodiment, R²⁰ is selected from the group consisting of H, C₁₋₃ alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent individually selected from the group consisting of halo, -OMe, and CF₃. Most preferably, R²⁰ is selected from the group consisting of H or C₁₋₃ alkyl and most preferably H or methyl.

In a preferred embodiment, R²² is selected from the group consisting of C₁₋₁₅ alkyl, aryl, or heteroaryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O-C₁₋₆ alkyl, CF₃, or heteroaryl.

In a most preferred embodiment, this invention is a substituted piperazine compound selected from the group consisting of N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, 2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, 4-(3-{4-[(2,6-dimethylphenyl)carbamoyl]-methyl}-piperazin-1-yl)-2-hydroxy-propoxy)-1H-indole-2-carboxylic acid amide, 2-{4-[3-(benzothiazol-6-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-dimethyl-piperazine-1-yl}acetamide, 2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-

dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy]-
 propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-
 yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-
 (pyridin-3-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-
 5 hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-
 {4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-
 dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-
 (2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-
 yl}acetamide, 2-{4-[3-(benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-
 10 dimethylphenyl)acetamide, 2-{4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-
 (2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-
 yloxy)propyl]-2,5-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-
 hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-
 dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-
 15 3,3-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-
 methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide,
 2-{(2R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2-methylpiperazinyl}-
 N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-
 yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-
 20 3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-
 dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2-
 methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-
 methylbenzothiazol-5-yloxy)propyl](1,4-diazaperhydroepinyl)}-N-(2,6-
 dimethylphenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-
 25 yloxy)propyl]piperazinyl}-N-(4-hydroxyphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-
 methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(4-
 carboxamidophenyl)acetamide, 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-
 yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-hydroxy-
 3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-
 30 {4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethyl-4-
 hydroxyphenyl)acetamide, 2-{5-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-
 2,5-diazabicyclo[2.2.1]hept-2-yl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-
 (2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-sulfamoylphenyl)acetamide, 2-{(3S)-

4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-naphthylacetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-phenylacetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide, 2-{4-[2-hydroxy-3-(4-methoxyphenyl)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2-chloro-4-methylphenyl)-acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,5-dichlorophenyl)-acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4-dichlorophenyl)-acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[3-methoxy-5-(trifluoromethyl)phenyl]acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[3,5-dichloro]phenyl]acetamide, and 2-{4-[2-hydroxy-3-(2-((1E)buta-1,3-dienyl)benzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-chloro-2-methoxy-5-methylphenyl]acetamide.

The following definitions apply to terms as used herein.

“Halo” or “Halogen” - alone or in combination means all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), iodo (I).

“Hydroxyl” refers to the group -OH.

“Thiol” or “mercapto” refers to the group -SH.

“Alkyl” - alone or in combination means an alkane-derived radical containing from 1 to 20, preferably 1 to 15, carbon atoms (unless specifically defined). It is a straight chain alkyl, branched alkyl or cycloalkyl. Preferably, straight or branched alkyl groups containing from 1-15, more preferably 1 to 8, even more preferably 1-6, yet more preferably 1-4 and most preferably 1-2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t-butyl and the like. The term “lower alkyl” is used herein to describe the straight chain alkyl groups described immediately above. Preferably, cycloalkyl groups are monocyclic, bicyclic or tricyclic ring systems of 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, adamantyl and the like. Alkyl also includes a straight chain or branched alkyl group that contains or is interrupted by a cycloalkyl portion. The straight chain or branched alkyl group is attached at any available point to produce a stable

compound. Examples of this include, but are not limited to, 4-(isopropyl)-cyclohexylethyl or 2-methyl-cyclopropylpentyl. A substituted alkyl is a straight chain alkyl, branched alkyl, or cycloalkyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like.

“Alkenyl” - alone or in combination means a straight, branched, or cyclic hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2 to 4 carbon atoms with at least one, preferably 1-3, more preferably 1-2, and most preferably one, carbon to carbon double bond. In the case of a cycloalkyl group, conjugation of more than one carbon to carbon double bond is not such as to confer aromaticity to the ring.

Carbon to carbon double bonds may be either contained within a cycloalkyl portion, with the exception of cyclopropyl, or within a straight chain or branched portion. Examples of alkenyl groups include ethenyl, propenyl, isopropenyl, butenyl, cyclohexenyl, cyclohexenylalkyl and the like. A substituted alkenyl is the straight chain alkenyl, branched alkenyl or cycloalkenyl group defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, carboxy, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, or the like attached at any available point to produce a stable compound.

“Alkynyl” - alone or in combination means a straight or branched hydrocarbon containing 2-20, preferably 2-17, more preferably 2-10, even more preferably 2-8, most preferably 2-4, carbon atoms containing at least one, preferably one, carbon to carbon triple bond. Examples of alkynyl groups include ethynyl, propynyl, butynyl and the like. A substituted alkynyl refers to the straight chain alkynyl or branched alkynyl defined previously, independently substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy,

alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, 5 arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like attached at any available point to produce a stable compound.

“Alkyl alkenyl” refers to a group $-R-CR'=CR''R'''$, where R is lower alkyl, or substituted lower alkyl, R', R'', R''' may independently be hydrogen, halogen, lower alkyl, 10 substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below.

“Alkyl alkynyl” refers to a groups $-RC\equiv CR'$ where R is lower alkyl or substituted lower alkyl, R' is hydrogen, lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined below.

15 “Alkoxy” denotes the group $-OR$, where R is lower alkyl, substituted lower alkyl, acyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroalkyl, heteroarylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, or substituted cycloheteroalkyl as defined.

“Alkylthio” denotes the group $-SR$, $-S(O)_{n=1-2}-R$, where R is lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl or substituted aralkyl as defined herein.

20 “Acyl” denotes groups $-C(O)R$, where R is hydrogen, lower alkyl substituted lower alkyl, aryl, substituted aryl and the like as defined herein.

“Aryloxy” denotes groups $-OAr$, where Ar is an aryl, substituted aryl, heteroaryl, or substituted heteroaryl group as defined herein.

25 “Amino” denotes the group NRR' , where R and R' may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, or substituted hetaryl as defined herein or acyl.

“Amido” denotes the group $-C(O)NRR'$, where R and R' may independently by hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, substituted hetaryl as defined herein.

30 “Carboxyl” denotes the group $-C(O)OR$, where R is hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, hetaryl, and substituted hetaryl as defined herein.

“Aryl” - alone or in combination means phenyl or naphthyl optionally carbocyclic fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members and/or optionally

substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted
5 with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like.

“Substituted aryl” refers to aryl optionally substituted with one or more functional groups, *e.g.*, halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl,
10 hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

“Heterocycle” refers to a saturated, unsaturated, or aromatic carbocyclic group having a single ring (*e.g.*, morpholino, pyridyl or furyl) or multiple condensed rings (*e.g.*, naphthpyridyl, quinoxalyl, quinolinyl, indolizinyl or benzo[b]thienyl) and having at least one
15 hetero atom, such as N, O or S, within the ring, which can optionally be unsubstituted or substituted with, *e.g.*, halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

“Heteroaryl” - alone or in combination means a monocyclic aromatic ring structure
20 containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group O, S, and N, and optionally substituted with 1 to 3 groups or substituents of halo, hydroxy, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, acyloxy, aryloxy, heteroaryloxy, amino optionally mono- or di-substituted with alkyl, aryl or
25 heteroaryl groups, amidino, urea optionally substituted with alkyl, aryl, heteroaryl or heterocyclyl groups, aminosulfonyl optionally N-mono- or N,N-di-substituted with alkyl, aryl or heteroaryl groups, alkylsulfonylamino, arylsulfonylamino, heteroarylsulfonylamino, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, or the like. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary
30 ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable aromatic ring is retained. Examples of heteroaryl groups are pyridinyl, pyridazinyl, pyrazinyl, quinazolinyl, purinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl,

imidazolyl, triazinyl, furanyl, benzofuryl, indolyl, benzothiazolyl, benzoxazolyl, and the like. A substituted heteroaryl contains a substituent attached at an available carbon or nitrogen to produce a stable compound.

“Heterocyclyl” - alone or in combination means a non-aromatic cycloalkyl group
5 having from 5 to 10 atoms in which from 1 to 3 carbon atoms in the ring are replaced by heteroatoms of O, S or N, and are optionally benzo fused or fused heteroaryl of 5-6 ring members and/or are optionally substituted as in the case of cycloalkyl. Heterocyclyl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. The point of attachment is at a carbon or nitrogen atom. Examples of heterocyclyl
10 groups are tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, piperazinyl, dihydrobenzofuryl, dihydroindolyl, and the like. A substituted heterocyclyl contains a substituent nitrogen attached at an available carbon or nitrogen to produce a stable compound.

“Substituted heteroaryl” refers to a heterocycle optionally mono or poly substituted with one or more functional groups, *e.g.*, halogen, lower alkyl, lower alkoxy, alkylthio,
15 acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

“Aralkyl” refers to the group -R-Ar where Ar is an aryl group and R is lower alkyl or substituted lower alkyl group. Aryl groups can optionally be unsubstituted or substituted with,
20 *e.g.*, halogen, lower alkyl, alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

“Heteroalkyl” refers to the group -R-Het where Het is a heterocycle group and R is a lower alkyl group. Heteroalkyl groups can optionally be unsubstituted or substituted with *e.g.*,
25 halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

“Heteroarylalkyl” refers to the group -R-HetAr where HetAr is an heteroaryl group and R lower alkyl or substituted lower alkyl. Heteroarylalkyl groups can optionally be unsubstituted or substituted with, *e.g.*, halogen, lower alkyl, substituted lower alkyl, alkoxy,
30 alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

“Cycloalkyl” refers to a divalent cyclic or polycyclic alkyl group containing 3 to 15 carbon atoms.

"Substituted cycloalkyl" refers to a cycloalkyl group comprising one or more substituents with, *e.g.*, halogen, lower alkyl, substituted lower alkyl, alkoxy, alkylthio, acetylene, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

5 "Cycloheteroalkyl" refers to a cycloalkyl group wherein one or more of the ring carbon atoms is replaced with a heteroatom (*e.g.*, N, O, S or P).

"Substituted cycloheteroalkyl" refers to a cycloheteroalkyl group as herein defined which contains one or more substituents, such as halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted
10 heterocycle, hetaryl, substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

"Alkyl cycloalkyl" denotes the group -R-cycloalkyl where cycloalkyl is a cycloalkyl group and R is a lower alkyl or substituted lower alkyl. Cycloalkyl groups can optionally be unsubstituted or substituted with *e.g.* halogen, lower alkyl, lower alkoxy, alkylthio, acetylene, amino, amido, carboxyl, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl,
15 substituted hetaryl, nitro, cyano, thiol, sulfamido and the like.

"Alkyl cycloheteroalkyl" denotes the group -R-cycloheteroalkyl where R is a lower alkyl or substituted lower alkyl. Cycloheteroalkyl groups can optionally be unsubstituted or substituted with *e.g.* halogen, lower alkyl, lower alkoxy, alkylthio, amino, amido, carboxyl, acetylene, hydroxyl, aryl, aryloxy, heterocycle, substituted heterocycle, hetaryl, substituted
20 hetaryl, nitro, cyano, thiol, sulfamido and the like.

"Optional" and "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, "optional pharmaceutical excipients" indicates that a formulation so described may or may not include
25 pharmaceutical excipients other than those specifically stated to be present, and that the formulation so described includes instances in which the optional excipients are present and instances in which they are not.


"Treating" and "treatment" refer to any treatment of a disease in a mammal, particularly a human, and include:

- 30 (i) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it;
- (ii) inhibiting the disease, *i.e.*, arresting its development; or
- (iii) relieving the disease, *i.e.*, causing regression of the disease.

All of the aforementioned embodiments include the pharmaceutically acceptable acid addition salts thereof, particularly the mono- and dihydrochlorides, and mixtures thereof.

The compounds having the general formula **Ia** ($q = O$) or **Ic** ($q = S$) can be prepared as outlined in Schemes 1-5. A general synthesis of the compounds of this invention is outlined in Scheme 1. Compound **IV** can be prepared by N-acylation of substituted aniline **II** with 2-substituted chloroacetylchloride **III**. Compound **II** is available commercially or readily prepared through reduction of the corresponding nitrobenzene derivative (acid/ SnCl_2 or catalytic hydrogenation, see Advanced Organic Chemistry, Ed. J. March, (1992) A. Wiley-Interscience). Some examples of commercially available substituted anilines corresponding to general structure **II** include 2,6-dimethylaniline, 2,3-dimethylaniline, 2-methylaniline, 4-methylaniline, 4-methylaniline, 2,4-dichloroaniline, 3,4-dichloroaniline, 2,5-dichloroaniline, 2,4-dichloroaniline, 2-chloroaniline, 3-chloroaniline, 2,6-difluoroaniline, 2,5-difluoroaniline, 3,4-difluoroaniline, 2-fluoroaniline, 4-fluoroaniline, 3-fluoroaniline, 2-fluoro-6-chloroaniline, 4-fluoro-3-chloroaniline, 4-acetoxyaniline.

SCHEME 1




Compound **VI** can be obtained by reacting compound **IV** with N-protected substituted piperazine **V** through warming in an appropriate solvent (e.g. DMF, EtOH). Protection of the nitrogen of compound **V** is only required when it is useful to control the regiochemistry of the addition of Compound **V** with compound **IV**. In some

- 5 cases, compound **V** can be obtained from commercial resources. Examples of commercially available compounds corresponding to general structure **V** include 2-methylpiperazine, 2,5-dimethylpiperazine, 2,6-dimethylpiperazine, 2,3,5,6-tetramethylpiperazine, piperazine-2-carboxylic acid, perhydroquinoxaline, 2-aminomethyl-6-methylpiperazine, 2-aminomethylpiperazine, 2-(*o*-chlorophenyl)piperazine, and 2-(*m*-chlorophenyl)piperazine.

Deprotection of compound **VI** can be accomplished using the standard conditions (e.g. for Boc group use TFA, for CBZ and benzyl use hydrogenation). Compound **Ia** or **Ic** can be prepared by reacting compound **VII** with epoxide **VIII** through warming in an appropriate solvent (ethanol, DMF, CHCl_3 , THF) or by stirring at room temperature in the presence of a
 5 lanthamide (III) Lewis acid (*Chini, M et al., Tetrahedron Lett., 35: 433-36 (1994)*).


SCHEME 2



Epoxide **VIII** (where $m = 1, 2$, or 3) can be prepared as outlined in Scheme 2. Heating
 10 substituted phenol, or thiophenol **IX** with epichlorohydrin, epibromohydrin, or 4-bromo-1,2-epoxybutane and potassium carbonate in acetone or sodium hydride in DMF can afford epoxide **VIII**. Compound **IX** can be obtained from commercial resources. Examples of commercially available compounds corresponding to structure **IX** include 2-methyl-5-hydroxybenzothiazole, 2-hydroxybenzothiazole, 8-hydroxyquinolidine, 6-hydroxyquinoline,
 15 4-hydroxyquinoline, 5-hydroxyisoquinoline, 3-hydroxypyridine, 2-quinoxalinol, and 4-(imidazol-1-yl)phenol. In some cases compound **VIII** can be obtained from commercial sources. Examples of commercially available compounds corresponding to general structure **VIII** include 4-glycidyloxy-2-indolecarboxamide.


Compound **IX** can in turn be prepared by the deprotection of the corresponding methyl
 20 or benzyl ethers (**X**) using Lewis acids as shown in Scheme 3 (BBr_3 , BF_3 , etc.- see Advanced Organic Chemistry, Ed. J. March (1992) A. Wiley Intersciences, p 434). Benzyl ethers can also be deprotected by refluxing with palladium hydroxide in ethanol/cyclohexene (see Catalytic hydrogenation over platinum metals, P. N. Rylander, Academic Press, New York, NY, (1976) p 464). Commercially available methyl ethers include 6-methoxy-2-methyl-
 25 benzothiazole.

SCHEME 3




Compound IX can also be prepared by the diazotization of the corresponding amino compounds (XI) as shown in Scheme 4 (Boggust, W. A and Cocker, W. J. Chem. Soc. 1949, 355). Commercially available amines include 6-amino-benzothiazole.

SCHEME 4




The 6, 5 fused ring system of compound X can be prepared by the cyclization of commercially available ethers of 2-aminophenols, 2-aminothiophenols, or 2-aminoanilines (XII) with orthoesters (XIII) (Musser, J. H. et al., J. Med. Chem. 1985, 28, 1255-1259) or imidates (XIV) (Gregory, G. I. Et al., J. Chem. Soc. Perkin Trans. 1, 1973, 47-51) as shown in Scheme 5 and 6 respectively. Commercially available, ethers of aminophenols include 4-methoxy-2-aminophenol, orthoesters include trimethyl orthoformate and trimethyl orthoacetate, imidates include ethyl acetimidate hydrochloride, and ethyl benzimidate hydrochloride.

SCHEME 5




5 SCHEME 6




The thiophenol analog of compound **XII** can be prepared from the commercially available compound **XV** by reacting with sodium disulfide hydrate followed by reduction using tin and hydrochloric acid (Dannley, R. L. and Zazaris, D. A; Can. J. Chem. **1965**, *43*, 2610-2612) as shown in Scheme 7. Commercially available nitro compounds include 3-nitro-4-chloroanisole.

SCHEME 7




Imidate **XIV** can be prepared by bubbling HCl gas through an alcoholic solution of the commercially available nitriles **XVI** as shown in Scheme 8. Commercially available nitriles include, benzonitrile, 4-trifluoromethylbenzonitrile and 3-trifluoromethylbenzonitrile.

SCHEME 8




Sulfur containing 6,5 fused ring system of compound X can also be prepared from the commercially available ethers of anilines **XVII** (Stevens, M. F. G. *et al*, J. Med. Chem. 1994, 37, 1689-1695) as shown in Scheme 9. Thioamide **XX** can be obtained by the reaction of Lawesson's reagent with amide **XIX** which in turn can be prepared by the reaction of compound **XVII** with compound **XVIII**. Cyclization of **XX** with potassium ferrocyanide under basic conditions can afford compound **XXI**. Commercially available ethers of anilines include benzyloxylanilines and anisidines.

SCHEME 9



A general synthesis of the compound **XXV** of this invention is outlined in Scheme 10. Compound **XXIV** can be prepared by the deprotection of compound **XXIII** using the standard conditions (e. g. for BOC group use TFA, for CBZ and benzyl use hydrogenation). Compound **XXIII** in turn can be prepared by the reaction of the commercially available protected monoketopiperazine analog compound **XXII** with compound **IV** and sodium hydride in an appropriate solvent (DMF, THF). An example of the commercially available monoketopiperazines include 4-benzyloxycarbonylpiperazine-2-one.


SCHEME 10



A general synthesis of the compound **Ib** (q = NH) of this invention is outlined in Schemes 11 and 12. Compound **XXVII** can be prepared by refluxing compound **VII** with the epoxide **XXVI** in a suitable solvent (ethanol, THF). Deprotection of compound **XXVII** can be accomplished by using standard conditions (e. g. for BOC group use TFA; for CBZ use hydrogenation or Pd(OH)₂). Compound **Ib** can be prepared by refluxing compound **XXVIII** with compound **XXIX** in a suitable solvent (ethanol, THF). Commercially available


compound **XXIX** includes 2-chlorobenzothiazole, 2-chlorobenzoxazole, 2-chloropyridine, 2-chloropyrimidine, 2-chloro-4-(trifluoromethyl)pyrimidine, and chloropyrazine.

SCHEME 11




Epoxide **XXVI** in turn can be prepared as shown in Scheme 12. Commercially available compound **XXX** can be protected using the standard conditions (for BOC protection use BOC anhydride; for CBZ protection use CBZ-Cl). Compound **XXV** can be prepared by the reaction of compound **XXXI** using m-chloroperbenzoic acid in a suitable solvent (e. g. dichloromethane). An example of a commercially available compound **XXX** includes by is not limited to allylamine.

SCHEME 12




Compound V can be prepared as described in Scheme 13. Alkylation of compound XXXII with alkyl halides using t-BuLi as base can afford compound XXXIII as described by Pohlman et. al. (J. Org. Chem, 1997, 62, 1016-1022). Reduction of XXXIV using diborane can afford the N-benzyl protected version of compound V after N-Boc deprotection with trifluoroacetic acid (TFA) [for the diborane reduction see Jacobson et. al, J. Med. Chem, 1999, 42, 1123-1144].

SCHEME 13




Compound V can also be prepared through standard coupling (eg. EDC or PyBroP) of D or L amino acids and standard deprotection as outlined in Scheme 14 (Cledera, P. et al. Tetrahedron, 1998 p. 12349-12360; Smith, R. A. et al Bioorg. Med. Chem. Lett. 1998, p. 2369-2374). Reduction of the diketopiperazine XXXVII with diborane can afford the N-benzyl protected version of compound V.

SCHEME 14




- Compound V can also be prepared as described in Scheme 15. Bromination of aldehydes XXXVIII followed by the reaction with ethylene diamine can afford the imine XLI. Catalytic hydrogenation of compound XLI can afford compound V (Bogeso, K. P., *et al*, J. Med. Chem. 1995, 38, p 4380-4392). Commercially available aldehydes include isobutyraldehyde.

10 SCHEME 15




Compound V also includes the bicyclic homologs of piperazine (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane 83, 3,8-diazabicyclo[3.2.1] octane 84, and 2,5-diazabicyclo[2.2.2] octane 85.




Commercially available bicyclic analogs include (1S,4S)-(+)-2,5-diazabicyclo[2.2.1]heptane **83**. Compounds **84**, **85**, and the (1R,4R) isomer of **83** can be prepared by published procedures (for **84** and **85**- see Sturm, P. A. *et al*, J. Med. Chem. 1974, 17, 481-487; for **83** see- Barish, T. F. and Fox, D. E. J. Org. Chem., 1990, 55, 1684-1687).

Specific examples of the preparation of compounds corresponding to the general schemes described above are disclosed in Scheme 16-29 of the Examples which further illustrate alternative methods for preparing compounds of this invention. In particular, 2,6-methylaniline was acylated with 2-chloroacetyl chloride **2** using saturated bicarbonate and ether (1:1) as base and co-solvent, respectively to afford the chloroacetamide derivative **3**. Further reaction of compound **3** with piperazine afforded compound **5** through warming in ethanol. Reaction of compound **5** with epoxide **6** by warming both components in ethanol at reflux afforded piperazine derivative **7** as illustrated in Scheme 16. Compound **6** was prepared by warming epichlorohydrin with the phenol **8** in acetone in the presence of K_2CO_3 as described in Scheme 17.

SCHEME 16




SCHEME 17




The benzoxazole derivative **8** was prepared by the deprotection of compound **13** as shown in Scheme 18. Compound **10** was prepared by condensation of 2-amino-4-methoxyphenol **12**. Compound **12** was obtained by the catalytic hydrogenation of the commercially available 4-methoxy-2-nitrophenol **11**, and the benzimidate derivative **13** as shown in Scheme 19. Compound **13** was obtained from 3-trifluoromethylbenzonitrile **14** using a Pinner reaction (ethanol/anhydrous HCl).

SCHEME 18




10

SCHEME 19




SCHEME 20



15


Synthesis of the key intermediates that were used in the preparation of the compounds described in this invention are shown in Scheme 21-25. Compound **16** was prepared by the diazotization of the commercially available 6-aminobenzothiazole as shown in scheme 21.

5 SCHEME 21




Compound **19** was prepared by condensation of compound **12** with trimethyl orthoacetate **18** as shown in Scheme 22.

10 SCHEME 22



Compound **22** can be prepared by the reduction of compound **21** with tin and hydrochloric acid as shown in Scheme 23. Compound **21** was synthesized by reacting compound **20** with sodium disulfide hydrate.


SCHEME 23



Compound **26** was prepared by the reaction of compound **25** with Lawesson's reagent as shown in Scheme 24. Compound **25** was prepared by the reaction of the aniline **23** with benzoyl chloride **24**. Cyclization of the thioamide **26** with potassium ferrocyanide in aqueous


sodium hydroxide gave a mixture of compounds 27 and 28. Compounds 27 and 28 were separated by column chromatography.

SCHEME 24




- 5 Debenzylation of compound 27 was carried out as shown in Scheme 25 by transfer hydrogenolysis using Pearlmann's catalyst in ethanol/cyclohexene.

SCHEME 25




- 10 Synthesis of compound 34 of this invention is described in Scheme 26. The amide 3 was prepared as described in Scheme 16. Reaction of 3 with the manion of the anion of the monoketopiperazine 30 formed through treatment with sodium hydride in DMF gave compound 31. Compound 34 was obtained through warming compound 32 with the epoxide 33 in ethanol. Compound 32 was prepared by the deprotection of compound 31 by catalytic
- 15 dehydrogenation. Epoxide 33 was prepared in the same manner as compound 6 described in Scheme 17.

SCHEME 26




Synthesis of a specific compound 39 of this invention is described in Scheme 27. The synthesis of compound 5 was described previously (Scheme 16). Warming compound 5 to reflux with the epoxide 35 in ethanol gave compound 36. Deprotection of 36 by treatment with palladium hydroxide in ethanol/cyclohexene under reflux conditions gave the amine 37. The final compound 39 was prepared by reacting 37 with 2-chlorobenzothiazole in ethanol and triethylamine.

SCHEME 27



Epoxide 35 was synthesized as described in Scheme 28. Allylamine 40 was reacted with benzyl chloroformate in dichloromethane to afford compound 42. Reaction of m-chloroperbenzoic acid with 42 gave the epoxide 35.

5 SCHEME 28



The acid addition salts of the compounds of this invention may be converted to the corresponding free base by treating with a suitable base, such as potassium carbonate or sodium hydroxide, typically in the presence of aqueous solvent, and at a temperature of between about 0 degrees C and 100 degrees C. The free base form is isolated by conventional means, such as extraction with an organic solvent.

Salts of the compounds of this invention may be interchanged by taking advantage of differential solubilities and volatilities, or by treating with the appropriately loaded ion exchange resin. This conversion is carried out at a temperature between about 0°C and the boiling point of the solvent being used as the medium for the procedure.

Administration of the active compounds and salts described herein can be via any of the accepted modes of administration for therapeutic agents. These methods include oral, parenteral, transdermal, subcutaneous and other systemic modes. The preferred method of administration is oral, except in those cases where the subject is unable to ingest, by himself, any medication. In those instances it may be necessary to administer the composition parenterally.

Depending on the intended mode, the compositions may be in the form of solid, semi-solid or liquid dosage forms, such as, for example, tablets, suppositories, pills, capsules, powders, liquids, suspensions, or the like, preferably in unit dosage forms suitable for single administration of precise dosages. The compositions may include one or more conventional pharmaceutical excipients and at least one active compound of this invention or the pharmaceutically acceptable salts thereof and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, diluents, etc.

The amount of active compound administered will, of course, be dependent on the subject being treated, the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician. However, an effective dosage is in the range of 0.1-30 mg/kg/day, preferably 0.5-20 mg/kg/day. For an average 70 kg human, this would amount to 7-2100 mg per day, or preferably 35-1400 mg/day. Since many of the effects of the compounds herein (protect skeletal muscles against damage resulting from trauma; protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication; treat shock conditions; preserve donor tissue and organs used in transplants; and treat cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, exercise induced angina, congestive heart disease, and myocardial infarction) are achieved through a similar mechanism (partial fatty acid oxidation inhibition) dosages (and forms of administration) are all generally within the same general and preferred ranges for all these utilities.

For solid compositions, conventional non-toxic solid include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like may be used. The active compound as defined above may be formulated as suppositories using, for example, polyalkylene glycols, for example, propylene glycol, as the carrier. Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a excipient, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol, and the like, to thereby form a solution or suspension. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, for example, sodium acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pennsylvania, 15th Edition, 1975. The composition or formulation to be administered will, in any event, contain a quantity of the active compound(s), a therapeutically effective amount, i.e. in an amount effective to alleviate the symptoms of the subject being treated. For oral administration, a pharmaceutically acceptable non-toxic composition is formed by the incorporation of any of the normally employed excipients, such as, for example pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin,

talcum, cellulose, glucose, sucrose, magnesium, carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such compositions may contain 10%-95% active ingredient, preferably 1-70%.

5 Parenteral administration is generally characterized by injection, either subcutaneously, intramuscularly or intravenously. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like. In addition, if desired, the pharmaceutical compositions
10 to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.

 A more recently devised approach for parenteral administration employs the implantation of a slow-release or sustained-release system, such that a constant level of
15 dosage is maintained. See, e.g., U.S. Pat. No. 3,710,795, which is incorporated herein by reference. In another recent approach, the compositions of this invention can be administered orally in a sustained release dosage form using the compositions and/or methods disclosed in U.S. Patent Application Serial No. 09/321,522, filed on May 27, 1999, the specification of which is incorporated herein by reference.


20 It is within the scope of this invention to administer one or more compounds of this invention to a mammal, and preferably to a human by other known routes of pharmaceutical dosage form administration including, but not limited to by bolus, intravenously, transdermally, through inhalation, sub-cutaneously, or any other therapeutic agent administration method or route known to one skilled in the art.

25 The following Examples are representative of the invention, but are not to be construed as limiting the scope of the claims.

Example 1

N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide (7):

5



10 Part A.

Synthesis of N-(2,6-dimethylphenyl)-2-chloroacetamide (3):

2,6-dimethylaniline (9.8 g, 81.2 mmol) was dissolved in ether (100 mL) and saturated aqueous NaHCO₃ (100 mL) and the reaction mixture was cooled in an ice/water bath. To the cold solution was added chloroacetyl chloride 2 (9.17 g, 81.2 mmol) dropwise over a period of 2 h. The mixture was allowed to warm to RT over 14 h. The mixture was extracted with ethyl acetate (3 X 50). The combined organic layers were dried over MgSO₄, filtered, and concentrated. The residue was triturated in ether and filtered to afford compound 3 as a white solid.

Part B.

20 **Synthesis of N-(2,6-dimethylphenyl)-piperazin-1-yl-acetamide (5):**

To a solution of compound 3 (5 g, 25.2 mmol) in ethanol (100 mL) was added piperazine 4 (2.1 g, 25.0 mmol) and N,N-diisopropylethylamine (3.2 g, 25.2 mmol). The reaction mixture was refluxed for 24 h. The mixture was concentrated *in vacuo* and the residue was purified by column chromatography (10:1 DCM: MeOH) to afford compound

25 5.

Part C.

Synthesis of 5-(oxiran-2-yl-methoxy)-2- [(3-trifluoromethyl)phenyl]benzoxazole (6):

1. **Synthesis of 2-amino-4-methoxyphenol (12):**

A solution of 4-methoxy-2-nitrophenol 11 (10g, 59.1 mmol) and Pd/C (1.0 g) in methanol (100 ml) was placed on a Parr shaker under H₂ (50 psi) for 60 minutes. The reaction mixture was filtered through Celite 521 and the filter cake washed with MeOH. The filtrate was evaporated (*in vacuo*), to yield compound 12 as a tan solid.

2. Synthesis of 3-trifluoromethyl-benzimidic acid ethyl ester hydrochloride (13):

To a solution of α,α,α -trifluoromethyl-m-tolunitrile **14** (1 g, 5.84 mmol) in EtOH (10 mL, anhydrous) was bubbled HCl (gas, anhydrous) for 10 minutes and the solution was stirred overnight. The solvent was evaporated to yield compound **13** as a white solid. The resulting solid was used in the next step without purification.

3. Synthesis of 5-methoxy-2- (3-trifluoromethylphenyl)-benzoxazole (10):

A solution of compound **13** and compound **12** (850 mg, 6.13 mmol) in THF (10 mL) was heated to reflux and allowed to stir overnight. The reaction mixture was allowed to cool and the THF evaporated (*in vacuo*). The residue was dissolved in ethyl acetate and washed with water. The organic layer was dried over MgSO₄ and treated with activated carbon Norit A. The mixture was filtered through Celite 521, and evaporated (*in vacuo*) and the residue was purified using column chromatography (20% Ethyl acetate/hexanes) to afford compound **10** as a light yellow solid.

4. Synthesis of 2-[(3-trifluoromethyl)phenyl]benzoxazol-5-ol (8):

To a solution of compound **10** (200 mg, 0.68 mmol) in CH₂Cl₂ (5 mL) was added BBr₃ (1M in CH₂Cl₂, 1 mL, 1 mmol) dropwise. The resulting solution was allowed to stir for 48 h. The solvent was removed by evaporation (*in vacuo*) and the residue was dissolved in ethyl acetate and washed with saturated NaHCO₃. The organic layer was dried over MgSO₄ and evaporated (*in vacuo*). The residue was purified using column chromatography (30% ethyl acetate/hexanes) to yield compound **8** as a white solid.


5. Synthesis of 5-(oxiran-2-yl-methoxy)-2- [(3-trifluoromethyl)phenyl]benzoxazole (6):

To a suspension of NaH (7 mg, 60% dispersion in oil, 0.18 mmol) in DMF (2 mL, anhydrous) was added a solution of compound **8** (54 mg, 0.19 mmol) in DMF (2 mL, anhydrous) dropwise. The solution was allowed to stir for 15 minutes. To the above solution epichlorohydrin (50 μ L, 0.63 mmol) was added and the resulting solution was allowed to stir overnight. The solvent was evaporated (*in vacuo*) and the residue dissolved in water and extracted with ethyl acetate. The organic layers were combined, dried over MgSO₄ and evaporated to yield compound **6** as a clear oil.


Part D.**Synthesis N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide (7):**

- 5 A solution of compound 5 (183 mg, 0.73 mmol) and compound 6 in EtOH (2 mL) and triethylamine (0.2 mL) was heated to 90 °C and allowed to stir overnight. The reaction mixture was allowed to cool and the solvent evaporated (*in vacuo*) to yield an oil. The oil was purified by prep TLC (5/0.5/94.5 MeOH/NH₄OH/CH₂Cl₂) to yield compound 7 as a white Solid: Mass Spectrum (MH⁺) = 583.4

10

Example 2**2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide (43):**

15

Synthesis of 2-(oxiran-2-ylmethoxy)benzothiazole (44):


Compound 44 was prepared in the manner of compound 6 substituting 2-hydroxy-benzothiazole for compound 8 in partC-5 of Example 1.

- 20 Compound 43 was prepared in the manner of compound 7 substituting compound 44 for compound 6 in part D of compound 7: Mass Spectrum (MH⁺) = 455.3.


Example 3

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (45):

5



Synthesis of 2-methyl-5-(oxiran-2-ylmethoxy)benzothiazole (33):




Compound 33 was prepared in the manner of compound 6 substituting 2-methyl-benzothiazol-5-ol for compound 8 in partC-5 of Example 1.

10

Compound 45 was prepared in the manner of compound 7 substituting compound 33 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 469.3

Example 4

4-(3-{4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl}-2-hydroxy-propoxy)-1H-indole-2-carboxylic acid amide (46):




5

Compound 19 was prepared in the manner of compound 7 substituting the commercially available 4-glycidyloxy-2-indolecarboxamide for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 480.4.


10

Example 5

2-{4-[3-(benzothiazol-6-yloxy)2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide (47):



15 **Synthesis of benzothiazol-6-ol (16):**


**16**

To a solution of 6-aminobenzothiazole (1.0 g, 6.66 mmol) in water (22 mL) and H_2SO_4 (16 mL) at 5 °C was added a solution of sodium nitrite (460 mg, 6.72 mmol) in water (13 mL) keeping the temperature below 5 °C. The resulting solution was allowed to stir for 15 minutes. The reaction mixture was heated to 160 °C and a solution of H_2SO_4 (50 mL) and

20

water (38 mL) was slowly added. The resulting mixture was allowed to stir for 1h. The mixture was allowed to cool and an aqueous solution of 50% sodium hydroxide was added until the pH=7. The mixture was extracted with ethyl acetate and washed with brine. The combined organic was dried over MgSO₄ and evaporated to yield a semi-solid. The semi-solid was purified by column chromatography (40% ethyl acetate /hexanes) to yield benzothiazol-6-ol **16** as an off-white solid.

Synthesis of 6-(oxiran-2-ylmethoxy)benzothiazole (48):




Compound **48** was prepared in the manner of compound **6** substituting compound **16** for compound **8** in part C-5 of Example 1.


Compound **47** was prepared in the manner of compound **7** substituting compound **48** for compound **6** in part D of compound **7**: Mass Spectrum (MH⁺) = 455.3.

Example 6

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}acetamide (49):




Synthesis of 2-methylbenzothiazol-6-ol (50):



Compound 50 was prepared from the commercially available 6-methoxy-2-methyl-benzothiazole as described in partC-4 of Example 1.

Synthesis of 2-methyl-6-(oxiran-2-ylmethoxy)benzothiazole (51):




Compound 51 was prepared in the manner of compound 6 substituting compound 50 for compound 8 in partC-5 of Example 1.


Compound 49 was prepared in the manner of compound 7 substituting compound 51 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 469.3.

Example 7

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-dimethyl-piperazine-1-yl}acetamide (52):



Synthesis of N-(2,6-dimethylphenyl)-2-C3,5-dimethylpiperazin-1-yl)acetamide (53):




Compound 53 was prepared in the manner of compound 3 substituting 2,6-dimethylpiperazine for piperazine in part A of Example 1.


Compound 52 was prepared in the manner of compound 7 substituting compound 33 for compound 6 and compound 53 for compound 5 in part D of compound 7: Mass Spectrum (MH^+) = 497.4.

Example 8

2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide (54):




5 Synthesis of 4-aminophenyl acetate (55):



55

Compound **55** was prepared in the manner of compound **12** substituting 4-nitrophenyl acetate for compound **11** in part C-1 of Example 1.

Synthesis of 4-(2-chloroacetyl-amino)phenyl acetate (56):




56

10

Compound **56** was prepared in the manner of compound **3** substituting compound **55** for compound **1** in part A of Example 1.

Synthesis of 4-(2-piperazinylacetyl-amino)phenyl acetate(57):



57


15

Compound **57** was prepared as described in part B of Example 1 substituting compound **56** for compound **3**.

Compound **54** was prepared in the manner of compound **7** substituting compound **33** for compound **6** and compound **57** for compound **5** in part D of compound **7**: Mass Spectrum (MH^+) = 457.5.


Example 9

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (58):



5


Synthesis of phenyl-N-[3-(phenylmethoxy)phenyl]carboxamide (25):



10 To a solution of 3-benzyloxyaniline **23** (1.0 g, 5.0 mmol) and TEA (0.74 mL, 5.3 mmol) in CH₂Cl₂ was added benzoyl chloride (0.61 mL, 5.26 mmol) dropwise and the mixture was allowed to stir overnight. The reaction mixture was diluted with water and the resulting solid was collected by vacuum filtration. The solid was allowed to air dry, to yield compound


15

Synthesis of phenyl-[(3-phenylmethoxy)phenyl]amino}methane-1-thione (26):




A solution of compound **25** (455 mg, 1.5 mmol) and Lawesson's reagent (0.6 mol equiv) in chlorobenzene (15 mL) was heated to 120 °C and allowed to stir for 1.5h. The reaction was allowed to cool and the solvent was evaporated (*in vacuo*). The residue was purified by column chromatography (ethyl acetate/hexane 1:9) to yield compound **26** as a yellow solid.


20

Synthesis of 2-phenyl-5-(phenylmethoxy)benzothiazole (27):

To a solution of compound 26 (960 mg, 3 mmol) in ethanol (5 mL) was added an aqueous sodium hydroxide solution (30%, 8 mol equiv). The mixture was diluted with water (6 mL) to give a final solution of 10% aqueous sodium hydroxide. The resulting solution was added to a stirred solution of potassium ferricyanide (4 mol equiv) in water at 90 °C in aliquots (1 mL) and the resulting mixture was heated for 30 min. The reaction mixture was allowed to cool and the product was extracted with ethyl acetate. The organic layer was dried and evaporated. The residue, a mixture of 27 and 28, was column purified (ethyl acetate/hexane - 1:99) to provide compound 27 as a white solid.

Synthesis of 2-phenylbenzothiazol-5-ol (29):

Palladium hydroxide (100 mg) was added to a solution of 27 (260 mg, 0.8 mmol) of ethanol/cyclohexene (5mL/2mL) followed by warming for reflux for 16h. The reaction mixture was cooled and the catalyst was removed by filtration (through Celite). The solvent was evaporated to provide compound 29 as a white solid.


Synthesis of 5-(oxiran-2-ylmethoxy)-2-phenylbenzothiazole (59):

Compound 59 was prepared in the manner of compound 6 substituting compound 29 for compound 8 in partC-5 of Example 1.

Compound 58 was prepared in the manner of compound 7 substituting compound 59 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 531.6


Example 10

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (60):



5

Synthesis of 5-(oxiran-2-ylmethoxy)-2-phenylbenzoxazole (61):




Compound 61 was prepared in the manner of compound 6 substituting ethyl benzimidate hydrochloride for compound 13 in part C1-5 of Example 1.

Compound 60 was prepared in the manner of compound 7 substituting compound 61 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 515.3.


10

Example 11

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-yl}acetamide (62):



5 Synthesis of 7-(oxiran-2-ylmethoxy)-2-phenylbenzothiazole (63):



63


Compound 63 was prepared in the manner of compound 59 substituting deprotected compound 28 for compound 29 in example 9.

Compound 62 was prepared in the manner of compound 7 substituting compound 63 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 531.3.


10

Example 12

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide (64):




Synthesis of phenylmethyl 4-{{N-(2,6-dimethylphenyl)carbamoyl}methyl}-3-oxopiperazinecarboxylate (31):



To a solution of compound 30 (252mg, 1.3mmol) in THF (13mL) and NaH (62mg, 1.6mmol) was added Compound 3 (300mg, 1.3mmol). The solution was allowed to stir under nitrogen overnight. The reaction was quenched with water (0.1mL) and dried over Na₂SO₄. The solution was concentrated and purified using column chromatography conditions to yield compound 31 as a solid.

Synthesis of N-(2,6-dimethylphenyl)-2-(2-oxopiperazinyl)-acetamide (32):




To a solution of compound 31 in methanol (10 mL) 10% palladium on carbon was added. The reaction vessel was charged with hydrogen (40p.s.i) and agitated for 4 h. The catalyst was removed by filtration and the filtrate was concentrated and purified using column chromatography (1:15 MeOH:DCM) to yield compound 32 as a semi solid.

Compound 64 was prepared in the manner of compound 7 substituting compound 33 for compound 6 and compound 32 for compound 5 in part D of compound 7: Mass Spectrum (MH⁺) = 483.3


Example 13

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide (65):



5


Synthesis of 5-methoxy-2-methyl-benzoxazole (19):



19

A solution of 2-amino-4-methoxyphenol **17** (8 g, 57.4 mmol) in trimethyl orthoacetate **18** (50 mL) was heated to reflux and allowed to stir for 24 h. The reaction was allowed to cool and the excess **18** was evaporated (*in vacuo*). The residue was dissolved in ethyl acetate and washed with water. The organic layer was dried over MgSO₄ and treated with activated carbon Norit A. The resulting solution was filtered through Celite 521 and evaporated to yield an oil. The oil was chromatographed on silica gel (20% ethyl acetate/hexanes) to yield compound **19** as a light yellow solid.

15 Synthesis of 2-methyl-5-oxiran-2-ylmethoxybenzoxazole (67):



67


Compound **67** was prepared in the manner of compound **6** substituting 6-hydroxy-2-methyl-benzoxazole **66** for compound **8** in part C-5 of Example 1.

Compound **66** in turn was obtained by the deprotection of compound **19** as described in part C-4 of Example 1.


Compound **65** was prepared in the manner of compound **7** substituting compound **67** for compound **6** in part D of compound **7**: Mass Spectrum (MH⁺) = 543.4

Example 14

N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide (68):



5 **Synthesis of 5-(oxiran-2-ylmethoxy)-2-(4-trifluoromethyl-phenyl)benzoxazole (69):**




69

Compound 69 was prepared in the manner of compound 6 substituting 4-trifluoromethylbenzimidic acid ethyl ester hydrochloride for compound 13 in part C1-5 of Example 1.


Compound 68 was prepared in the manner of compound 7 substituting compound 69
10 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 583.4

Example 15

15 N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl}acetamide (70):



Synthesis of 2-(oxiran-2-ylmethoxy)quinoxaline (71):



71


Compound 71 was prepared in the manner of compound 6 substituting quinoxaline-2-ol for compound 8 in part C-5 of Example 1.

Compound 70 was prepared in the manner of compound 7 substituting compound 71 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 450.9.


5

Example 16

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(pyridin-3-yloxy)-propyl]-piperazin-1-yl}acetamide (72):



10 Synthesis of 3-(oxiran-2-ylmethoxy)pyridine (73):




73

Compound 73 was prepared in the manner of compound 6 substituting 3-hydroxypyridine for compound 8 in part C-5 of Example 1.

Compound 72 was prepared in the manner of compound 7 substituting compound 73 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 399.4.


Example 17

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl}acetamide (74):



5

Synthesis of 4-(oxiran-2-ylmethoxy)quinoline (75):




Compound 75 was prepared in the manner of compound 6 substituting 4-hydroxy-quinoline for compound 8 in part C-5 of Example 1.

10 Compound 74 was prepared in the manner of compound 7 substituting compound 75 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 449.4.

Example 18

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide (76):

15




Synthesis of 5-(oxiran-2-ylmethoxy)isoquinoline (77):

Compound 77 was prepared in the manner of compound 6 substituting 5-hydroxy-isoquinoline for compound 8 in part C-5 of Example 1.


20 Compound 76 was prepared in the manner of compound 7 substituting compound 77 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 449.4.

Example 19

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide (78):



5 **Synthesis of 6-(oxiran-2-ylmethoxy)quinoline (79):**




Compound 79 was prepared in the manner of compound 6 substituting 6-hydroxy-quinoline for compound 8 in part C-5 of Example 1.

Compound 78 was prepared in the manner of compound 7 substituting compound 79 for compound 6 in part D of compound 7: Mass Spectrum (MH^+) = 449.4


10

Example 20

N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl}acetamide (80):



15 **Synthesis of 2-methyl-7-(oxiran-2-ylmethoxy)quinoline (81):**




Compound 81 was prepared in the manner of compound 6 substituting 7-hydroxy-2-methyl-quinoline for compound 8 in part C-5 of Example 1.


Compound **80** was prepared in the manner of compound **7** substituting compound **81** for compound **6** in part D of compound **7**: Mass Spectrum (MH^+) = 463.5.

Example 21

- 5 **2-{4-[3-(benzothiazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide (39):**




Synthesis of (phenylmethoxy)-N-prop-2-enylcarboxamide (42):



- 10 To a solution of allylamine (3.34 g, 5.85mmol) in dichloromethane (100mL) and triethylamine (16 mL) benzyl chloroformate (8.25 mL, 5.78mmol) was added at 0 °C. The mixture was stirred at 0 °C for 2hours and additional 90 minutes at RT. The solvent was removed by evaporation and the residue was purified by flash column chromatography (30% EtOAc/Hexanes) to yield compound **42** as a clear oil.


15

Synthesis of N-(oxiran-2-ylmethoxy)(phenylmethoxy)carboxamide (35):



- 20 Compound **42** (5.0 g, 2.61 mmol) was treated with m-chloroperbenzoic acid (11.71 g, 9.1 mmol) in dichloromethane (110 mL) at room temperature for 18h. Dichloromethane was evaporated to afford a viscous oil which was then purified by flash column chromatography (30%EtOAc/Hexanes) to give compound **35** as a clear oil .


Synthesis of N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[phenylmethoxy]carbonylamino}propyl)piperazinyl)acetamide (36):



36

A solution of compound 42 (2.5 g, 1.2 mmol) and compound 5 (5.94 g, 2.4 mmol) in ethanol (100 mL) and triethylamine (3.34 mL) was refluxed for 18h. Solvents were removed and the residue was purified by flash column chromatography (ethyl acetate) to afford compound 36 as a white solid.

Synthesis of 2-[4-(3-amino-2-hydroxypropyl)piperazinyl]-N-(2,6-dimethylphenyl)acetamide (37):




37

A solution of compound 36 (3.0 g, 0.66 mmol) in methanol (70 mL) in presence of 10% Palladium on Carbon (0.337 g) was stirred under hydrogen atmosphere for 16h. Filtration of catalyst followed by concentration afforded compound 37 as a sticky solid.

To a solution of compound 37 (75 mg) in ethanol (2 mL) was added triethylamine (0.13 mL) and 2-chlorobenzthiazole (87 mg) followed by warming to reflux for 16h. The reaction mixture was concentrated and purified by preparative TLC (5%MeOH/Dichloromethane) to give Compound 39 as a white solid. Mass Spectrum (MH⁺) = 454.4.

Example 22

2-[4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl]-N-(2,6-dimethylphenyl)acetamide (82):



82

Compound **82** was prepared in the manner of compound **39** by substituting 2-chloro-benzoxazole for 2-chloro-benzothiazole as in example 21. Mass Spectrum (MH^+) = 438.4.

The following compounds were made in the same manner as shown in Examples 1-21. The

5 compounds all provided satisfactory mass spectrum data (MH^+).

2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,5-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

10 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,3-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

15 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

2-{(2R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

20 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

25 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

30 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl](1,4-diazaperhydroepinyl)}-N-(2,6-dimethylphenyl)acetamide

2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-hydroxyphenyl)acetamide

35 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(4-carboxamidophenyl)acetamide

40 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide

2-{4-[(2R)-2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide

45 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethyl-4-hydroxyphenyl)acetamide

- 2-{5-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,5-diazabicyclo[2.2.1]hept-2-yl}-N-(2,6-dimethylphenyl)acetamide
- 5 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-sulfamoylphenyl)acetamide,
- 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide
- 10 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-naphthylacetamide
- N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl} acetamide
- 15 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-phenylacetamide
- 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide
- 20 2-{4-[2-hydroxy-3-(4-methoxyphenyl)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide
- 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2-chloro-4-methylphenyl)-acetamide
- 25 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide
- 30 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,5-dichlorophenyl)-acetamide
- 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4-dichlorophenyl)-acetamide
- 35 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[3-methoxy-5-(trifluoromethyl)phenyl]acetamide
- 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[3,5-dichlorophenyl]acetamide
- 40 2-{4-[2-hydroxy-3-(2-((1E)buta-1,3-dienyl)benzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-chloro-2-methoxy-5-methylphenyl]acetamide

Example 23

Mitochondrial Assays

Rat heart mitochondria were isolated by the method of Nedergard and Cannon
5 (Methods in Enzymol. 55, 3, 1979).

Palmitoyl CoA oxidation – The Palmitoyl CoA oxidation was carried out in a total
volume of 100 micro liters containing the following agents: 110 mM KCl, 33 mM Tris buffer
at pH 8, 2 mM KPi, 2 mM MgCl₂, 0.1 mM EDTA, 14.7 microM defatted BSA, 0.5 mM malic
acid, 13 mM carnitine, 1 mM ADP, 52 micrograms of mitochondrial protein, and 16 microM
10 1-C¹⁴ palmitoyl CoA (Sp. Activity 60 mCi/mmol; 20 microCi/ml, using 5 microliters per
assay). The compounds of this invention were added in a DMSO solution at the following
concentrations: 100 microM, and 50 microM. In each assay, a DMSO control was used.
After 15 min at 30 oC, the enzymatic reaction was centrifuged (20,000 g for 1 min), and 70
microliters of the supernatant was added to an activated reverse phase silicic acid column
15 (approximately 0.5 ml of silicic acid). The column was eluted with 2 ml of water, and 0.5 ml
of the eluent was used for scintillation counting to determine the amount of C¹⁴ trapped as C¹⁴
bicarbonate ion.

Table 1

**Inhibition of mitochondrial fatty acid oxidation using palmitoyl CoA as substrate - % of
20 Control at 2 concentrations and IC₅₀.**

Compound #	100 μ m (%)	50 μ m (%)	IC ₅₀ (μ m)
7	--	77	--
39	27	--	--
43	21	--	--
45	87	--	~20
46	61	--	~125
47	70	--	~125
49	3	--	--
52	95	--	~1
54	81	--	~8
60	--	61	--
62	--	62	--
64	41	--	--

68	--	68	--
70	12	--	--
72	8	--	--
74	12	--	--
76	26	--	--
78	42	--	--
80	22	--	--
82	22	--	--

Example 25

Metabolic Stability: As a measure of metabolic stability the compounds of this invention were incubated with human liver S-9 microsomal fractions. After, 30 minutes at 37 C, the amount of parent drug remaining was determined using LC-mass spec. The response factors for each compound was determined by establishing a standard curve and using an internal standard during the analysis of the samples. An average of five experiments for percentage of ranolazine remaining at the 30 minute time point is 57%. The compounds of this invention were assayed as described in the protocol below and the percentage of parent remaining was divided by the average % of ranolazine remaining (57%) affording a metabolic stability factor. A compound with a stability number greater than 1.2 has a better stability than ranolazine in the liver S-9 assay. A compound with a stability number between 1.2 and 0.8 has an equivalent stability in the liver S-9 assay. A compound with a stability number less than 0.8 is less stable than ranolazine in the liver S-9 assay.

The purpose of this experiment is to compare the percentages remaining for compounds of this invention with the percentage remaining for ranolazine after 30 minutes of incubation with human liver S9 fractions.

Reagents:

The following reagents were used; Potassium phosphate, 0.5M pH 7.4 (incubation buffer), kept at room temperature; 0.05M MgCl₂ kept at 4°C; β-Nicotinamide adenine dinucleotide phosphate, tetrasodium salt, reduced form (NADPH), 0.02M solution in water (~16.6mg/mL) from Sigma Lot # 79H7044 prepared on day of use. 1mM of ranolazine or Compounds 43, 45, 47, 52, 70, 74, 76, 78, and 80 in ACN further diluted to obtain 100μM in 10% ACN; Human S9 stock: 20mg/mL from Gentest.

Procedure:

Incubation mixtures were prepared as follows:

Table 2

Component	Volume per 0.25mL of Incubation Mixture	Final concentration
10μM CVT compounds	25μL	10 μM
MgCl ₂	25μL	0.005 M
NADPH	25μL	0.002 M
S9	25μL	2 mg/mL
Incubation Buffer	25μL	0.05 M
Water	125μL	----

* 1% organic solvent (acetonitrile) was used in incubation mixture. Generally, 30 incubates were prepared at a time by pre-mixing 0.75 mL of MgCl₂, 0.75 mL of incubation buffer, 0.75 mL of NADPH, 3.75 mL of water. Then pipette 200 μL/incubate, add 25 μL of compound being tested, mix, and initiate reaction by addition of S-9.

Combine all components with incubation buffer and re-pipette 200 μL/tube + 25μL of the compound being tested along with 25μL of S-9.

After 5 min of pre-incubation at 37°C, at 0 and 30min after starting the reaction, a 50 μL aliquot of the incubation mixture was removed and added to 100 μL of 9:1 acetonitrile: methanol containing the internal standard.

The mixture was centrifuged and a 100 μL aliquot of the supernatant was diluted in 1mL of solvent C (0.1% Formic Acid in water). Then samples were analyzed for change between the ratio of compound to internal standard at time zero and 30 minutes by LC/MS (injected 10 μL).

Analytical and Data Calculations:


Samples were analyzed for the starting compounds and potential metabolite/s by LC/MS using an internal standard and an ODS-C18 column with a flow rate of 0.25 ml/min. Following the above procedure resulted in the following relative stability factors as compared to ranolazine for the compounds of this invention as illustrated in Table 3.

Table 3

Compound #	Liver S9 Stability Factor
43	0.6
45	0.8
46	1.1
47	1.5
52	0.5
70	0.1
74	1.0
76	0.8
78	0.6
80	0.5

We claim:

1. A substituted piperazine compound having the following formula:



wherein $m = 1, 2, \text{ or } 3$;

$q = \text{NH}, \text{O}, \text{ or } \text{S}$;

- 5 R^1, R^2, R^3, R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl and aryl substituent are optionally substituted with 1 substituent selected from the group consisting of halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, and SO_2R^{22} and wherein R^1 and R^2 or R^2 and R^3 or R^3 and R^4 or R^4 and R^5 when taken together with the carbons to which they are attached may form a 6-membered aromatic ring that is optionally substituted by alkyl, trifluoroalkyl, alkoxy, or halogen;
- 10

- R^6, R^7 and R^8 each independently selected from the group consisting of hydrogen or C_{1-3} alkyl;
- 15

- $R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}$ and R^{16} are each independently selected from the group consisting of hydrogen, CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, C_{1-4} alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , CN , OR^{20} , $\text{N}(\text{R}^{20})_2$, CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$ or aryl, wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl with the proviso that R^{11} and R^{13} or R^9 and R^{15} or R^9 and R^{11} or R^{11} and R^{15} or R^9 and R^{13} may join together to form a ring including from 1 to 3 carbon atoms;
- 20

- R^{17} is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, or heteroaryl, wherein
- 25

the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or SO₂R²²;

R²⁰ is selected from the group consisting of H, C₁₋₁₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, mono- or dialkylamino, alkyl, CN, -O-C₁₋₆ alkyl, or CF₃; and

R²² is selected from the group consisting of C₁₋₁₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O-C₁₋₆ alkyl, CF₃, or heteroaryl.

2. The compound of claim 1 wherein q = NH or O;

R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, halo, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, SO₂N(R²⁰)₂, CO₂R²⁰, CON(R²⁰)₂, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or SO₂R²²;

R⁶, R⁷ and R⁸ each independently selected from the group consisting of hydrogen or C₁₋₃ alkyl;

R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶ are each independently selected from the group consisting of hydrogen, CON(R²⁰)₂, C₁₋₄ alkyl, or wherein R⁹ and R¹⁰ may together form a carbonyl, or R¹¹ and R¹² may together form a carbonyl, or R¹³ and R¹⁴ may together form a carbonyl, or R¹⁵ and R¹⁶ may together form a carbonyl;

R¹⁷ is heteroaryl that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, NR²⁰CO₂R²², NR²⁰CON(R²⁰)₂, CO₂R²⁰, CON(R²⁰)₂, NR²⁰SO₂R²², C₁₋₁₅ alkyl, C₂₋₁₅ alkenyl, C₂₋₁₅ alkynyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or SO₂R²²; and

R²⁰ is selected from the group consisting of H, C₁₋₁₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkylcyano, -O-C₁₋₆ alkyl, or CF₃.

3. The compound of claim 1 wherein R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , C_{1-5} alkyl, C_{2-5} alkenyl, or C_{2-5} alkynyl, wherein the alkyl substituent is optionally substituted with CF_3 ;

5 R^6 , R^7 and R^8 are each independently selected from the group consisting of hydrogen or C_{1-3} alkyl;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, $CON(R^{20})_2$, or C_{1-4} alkyl wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl;

10 R^{17} is heteroaryl that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , OR^{20} , or $N(R^{20})_2$; and

15 R^{20} is selected from the group consisting of H, C_{1-8} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, $-O-C_{1-3}$ alkyl, or CF_3 .

4. The composition of claim 1 wherein R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , C_{1-3} alkyl, C_{2-3} alkenyl, or C_{2-3} alkynyl, wherein the alkyl is optionally substituted with CF_3 ;

20 R^6 , R^7 and R^8 each independently selected from the group consisting of hydrogen or methyl;

25 R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen or C_{1-2} alkyl, wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl;

30 R^{17} is a heteroaryl that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-5} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , OR^{20} , or $N(R^{20})_2$; and

R^{20} is selected from the group consisting of H, C_{1-5} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, -OMe, or CF_3 .

5. The composition of claim 1 wherein $m = 1$;

5 R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , or C_{1-3} alkyl wherein the alkyl substituent is optionally substituted with CF_3 ;

R^6 , R^7 and R^8 each independently selected from the group consisting of hydrogen or methyl;

10 R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, or methyl, wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl;

15 R^{17} is a heteroaryl that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-3} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF_3 , OR^{20} , or $N(R^{20})_2$; and

20 R^{20} is selected from the group consisting of H, C_{1-3} alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent individually selected from the group consisting of halo, -OMe, and CF_3 .

6. The compound of claim 1 wherein R^{17} is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 5 heteroatoms each selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22} , $SO_2N(R^{20})_2$, $NR^{20}CO_2R^{22}$, $NR^{20}CON(R^{20})_2$, COR^{20} , CO_2R^{20} , $CON(R^{20})_2$, $NR^{20}SO_2R^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, or SO_2R^{22} .

7. The composition of claim 6 wherein $q = NH$, O;

R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $SO_2N(R^{20})_2$, CO_2R^{20} , $CON(R^{20})_2$, C_{1-8} alkyl,

C₂₋₈ alkenyl, C₂₋₈ alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or SO₂R²²;

R⁶, R⁷ and R⁸ each independently selected from the group consisting of hydrogen or
5 C₁₋₃ alkyl;

R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶ are each independently selected from the group consisting of hydrogen, CON(R²⁰)₂, C₁₋₄ alkyl, or aryl wherein the alkyl and aryl substituents are each optionally substituted with 1 substituent selected from the group consisting of halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂ or aryl wherein R⁹ and R¹⁰ may together form a carbonyl, or
10 R¹¹ and R¹² may together form a carbonyl, or R¹³ and R¹⁴ may together form a carbonyl, or R¹⁵ and R¹⁶ may together form a carbonyl with the proviso that R¹¹ and R¹³ or R⁹ and R¹⁵ or R⁹ and R¹¹ or R¹¹ and R¹⁵ or R⁹ and R¹³ may join together to form a ring;

R¹⁷ is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 4 heteroatoms each selected from the group consisting of N, O, and S that is optionally
15 substituted with 1-3 substituents selected from the following hydrogen, halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, NR²⁰CO₂R²², NR²⁰CON(R²⁰)₂, CO₂R²⁰, CON(R²⁰)₂, NR²⁰SO₂R²², C₁₋₁₅ alkyl, C₂₋₁₅ alkenyl, C₂₋₁₅ alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or
20 SO₂R²²; and

R²⁰ is selected from the group consisting of H, C₁₋₁₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl-CN, -O-C₁₋₆ alkyl, or CF₃.

25 8. The composition of claim 6 wherein q = NH or O;

R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, C₁₋₅ alkyl, C₂₋₅ alkenyl, or C₂₋₅ alkynyl, wherein the alkyl substituent is optionally substituted with CF₃ or wherein R¹ and R² or R² and R³ or R³ and R⁴ or R⁴ and R⁵ when taken together with the carbons to which they are attached may form a 6-
30 membered aromatic ring that is optionally substituted by alkyl, trifluoroalkyl, alkoxy, or halogen;

R⁶, R⁷ and R⁸ each independently selected from the group consisting of hydrogen or C₁₋₃ alkyl;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, $\text{CON}(R^{20})_2$, C_{1-3} alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, $\text{N}(R^{20})_2$, and aryl or wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl with the proviso that R^{11} and R^{13} or R^9 and R^{15} or R^9 and R^{11} or R^{11} and R^{15} or R^9 and R^{13} may join together to form a ring;

R^{17} is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 3 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $\text{N}(R^{20})_2$, $\text{CON}(R^{20})_2$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF_3 , OR^{20} , or $\text{N}(R^{20})_2$; and

R^{20} is selected from the group consisting of H, C_{1-8} alkyl, aryl, or heteroaryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, $-\text{O}-C_{1-3}$ alkyl, or CF_3 .

9. The compound of claim 6 wherein $q = \text{NH}$ or O;

R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , C_{1-3} alkyl, C_{2-3} alkenyl, or C_{2-3} alkynyl, wherein the alkyl substituent is optionally substituted with CF_3 ;

R^6 , R^7 and R^8 each independently selected from the group consisting of hydrogen or methyl;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, $\text{CON}(R^{20})_2$, C_{1-3} alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, $\text{N}(R^{20})_2$, or aryl wherein R^9 and R^{10} may together form a carbonyl with the proviso that R^{11} and R^{13} or R^9 and R^{15} or R^9 and R^{11} or R^{11} and R^{15} or R^9 and R^{13} may join together to form a ring;

R^{17} is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 2 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $\text{N}(R^{20})_2$, $\text{CON}(R^{20})_2$, C_{1-4} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , or OR^{20} ; and

R^{20} is selected from the group consisting of H, C_{1-5} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, -OMe, or CF_3 .

10. The compound of claim 6 wherein $q = NH$ or O;

5 R^1, R^2, R^3, R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , or C_{1-3} alkyl wherein the alkyl substituent is optionally substituted with CF_3 and wherein R^2 and R^3 when taken together with the carbons to which they are attached may form a 6-membered aromatic ring that is optionally substituted by alkyl, trifluoroalkyl, alkoxy, or halogen;

10 R^6, R^7 and R^8 each independently selected from the group consisting of hydrogen or methyl;

$R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}$ and R^{16} are each independently selected from the group consisting of hydrogen, or C_{1-2} alkyl, wherein the alkyl substituent is optionally substituted with 1 substituent selected from the group consisting of $N(R^{20})_2$, or aryl or wherein R^9 and R^{10}
15 may together form a carbonyl;

R^{17} is a heteroaryl that is a fused 6,5 membered ring system containing from 1 to 2 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-3} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are
20 optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , or OR^{20} ; and

R^{20} is selected from the group consisting of H, C_{1-3} alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, -OMe, or CF_3 .

25 11. The composition of claim 10 wherein $q = O$; and

R^{17} is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of indole, benzothiazole, and benzoxazole that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-3} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are
30 optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , or OR^{20} .

12. The composition of claim 10 wherein $q = O$;

R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, CF_3 , OR^{20} , or C_{1-2} alkyl and wherein R^2 and R^3 when taken together with the
5 carbons to which they are attached may form a 6-membered aromatic ring that is optionally substituted by alkyl, trifluoroalkyl, alkoxy, or halogen;

R^6 , R^7 and R^8 are each hydrogen;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen or C_{1-2} alkyl, or wherein R^9 and R^{10} may together form a carbonyl;

10 R^{17} is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of indole, benzothiazole, and benzoxazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-3} alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF_3 ; and

15 R^{20} is selected from the group consisting of H or C_{1-3} alkyl.

13. The compound of claim 12 wherein R^{17} is benzothiazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-3} alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF_3 .

20 14. The compound of claim 12 wherein R^{17} is benzothiazole that is optionally substituted at the 2-position with 1 substituent selected from the group consisting of hydrogen, methyl or phenyl.

15. The compound of claim 12 wherein R^{17} is 5-substituted benzothiazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, halo,
25 CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-3} alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF_3 .

R^{20} is selected from the group consisting of H or methyl.

16. A compound of claim 12 wherein R^{17} is 5-substituted benzothiazole that is optionally substituted at the 2-position with 1 substituent selected from the group consisting
30 of hydrogen, methyl or phenyl; and

R^{20} is selected from the group consisting of H or methyl.

17. A compound of claim 12 wherein $q = O$;

R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, OR^{20} , or methyl;

R^6 , R^7 and R^8 are each hydrogen;

R^{11} and R^{15} are each selected from the group consisting of hydrogen or methyl, R^9 ,

5 R^{10} , R^{12} , R^{13} , R^{14} and R^{16} are each hydrogen and R^9 and R^{10} may together form a carbonyl;

R^{17} is 5-substituted benzothiazole that is substituted at the 2-position with methyl; and R^{20} is H.

18. A compound of claim 12 wherein $q = O$;

10 R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, OR^{20} , or methyl;

R^6 , R^7 and R^8 are each hydrogen;

R^{11} and R^{15} are each selected from the group consisting of hydrogen or methyl, R^9 ,

R^{10} , R^{12} , R^{13} , R^{14} and R^{16} are each hydrogen and R^9 and R^{10} may together form a carbonyl;

15 R^{17} is 5-substituted benzothiazole that is substituted at the 2-position with phenyl; and R^{20} is H.

19. A compound of claim 12 wherein $q = O$;

R^1 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, OR^{20} , or methyl and wherein R^2 and R^3 when taken together with the carbons to which they are attached may form a 6-membered aromatic ring that is optionally substituted by alkyl, trifluoroalkyl, alkoxy, or halogen;

20 R^6 , R^7 and R^8 are each hydrogen;

R^{11} and R^{15} are each selected from the group consisting of hydrogen or methyl, R^9 , R^{10} , R^{12} , R^{13} , R^{14} and R^{16} are each hydrogen and R^9 and R^{10} may together form a carbonyl;

25 R^{17} is 5-substituted benzothiazole that is substituted at the 2-position with methyl; and R^{20} is H.

20. A compound of claim 6 or 7 or 8 or 9 or 10 or 11 or claim 12 or 13 or 14 or 15 or 16 wherein R^{17} is 5-substituted benzothiazole that is substituted at the 2-position with methyl.

21. A compound of claim 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15, or 16
30 wherein R^{17} is 5-substituted benzothiazole that is substituted at the 2-position with phenyl.

22. The compound of claim 1 wherein R^{17} is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 4 nitrogen atoms that is optionally substituted

with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², SO₂R²², SO₂N(R²⁰)₂, NR²⁰CO₂R²², NR²⁰CON(R²⁰)₂, COR²⁰, CO₂R²⁰, CON(R²⁰)₂, NR²⁰SO₂R²², C₁₋₁₅ alkyl, C₂₋₁₅ alkenyl, C₂₋₁₅ alkynyl,

heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally

- 5 substituted with 1 substituent independently selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or SO₂R²².

23. The compound of claim 22 wherein q = O;

R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, halo, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, SO₂N(R²⁰)₂, CO₂R²⁰, CON(R²⁰)₂, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, NO₂, CF₃, CN, OR²⁰, SR²⁰, N(R²⁰)₂, S(O)R²², or SO₂R²²;

R⁶, R⁷ and R⁸ each independently selected from the group consisting of hydrogen or C₁₋₃ alkyl;

- 15 R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶ are each independently selected from the group consisting of hydrogen, CON(R²⁰)₂, C₁₋₄ alkyl, or aryl wherein the alkyl and aryl substituents are each optionally substituted with 1 substituent selected from the group consisting of halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂ or aryl wherein R⁹ and R¹⁰ may together form a carbonyl, or R¹¹ and R¹² may together form a carbonyl, or R¹³ and R¹⁴ may together form a carbonyl, or R¹⁵ and R¹⁶ may together form a carbonyl with the proviso that R¹¹ and R¹³ or R⁹ and R¹⁵ or R⁹ and R¹¹ or R¹¹ and R¹⁵ or R⁹ and R¹³ may join together to form a ring;

R²⁰ is selected from the group consisting of H, C₁₋₁₅ alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl-CN, -O-C₁₋₆ alkyl, or

- 25 CF₃; and

24. The compound of claim 22 wherein q = O;

R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, C₁₋₅ alkyl, C₂₋₅ alkenyl, or C₂₋₅ alkynyl, wherein the alkyl substituent is optionally substituted with CF₃;

- 30 R⁶, R⁷ and R⁸ each independently selected from the group consisting of hydrogen or C₁₋₃ alkyl;

R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶ are each independently selected from the group consisting of hydrogen, CON(R²⁰)₂, C₁₋₃ alkyl, or aryl wherein the alkyl and aryl substituents

are optionally substituted with 1 substituent selected from the group consisting of halo, $N(R^{20})_2$, and aryl or wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl with the proviso that R^{11} and R^{13} or R^9 and R^{15} or R^9 and R^{11} or R^{11} and R^{15} or R^9 and R^{13} may join together to form a ring;

- 5 R^{17} is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 3 nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF_3 ,
10 OR^{20} , or $N(R^{20})_2$; and

R^{20} is selected from the group consisting of H, C_{1-8} alkyl, aryl, or heteroaryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, $-O-C_{1-3}$ alkyl, or CF_3 .

25. The compound of claim 22 wherein $q = O$;

- 15 R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, OR^{20} , or methyl;

R^6 , R^7 and R^8 each hydrogen;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, C_{1-2} alkyl, or R^9 and R^{10} may together form a carbonyl;

- 20 R^{17} is a heteroaryl that is a fused 6, 6 membered ring system containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl; and

R^{20} is H.

26. The compound of claim 22 wherein $q = O$;

- 25 R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen or methyl;

R^6 , R^7 and R^8 each hydrogen;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each hydrogen; and

R^{17} is a heteroaryl that is a fused 6, 6-membered ring system containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl.

- 30 27. The compound of claim 1 wherein R^{17} is a 5 or 6-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, S, or O that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN, OR^{20} , SR^{20} , $N(R^{20})_2$, $S(O)R^{22}$, SO_2R^{22} , $SO_2N(R^{20})_2$, $NR^{20}CO_2R^{22}$,

$\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, or SO_2R^{22} .

5 28. The compound of claim 27 wherein $q = \text{O}$;

R^1 , R^2 , R^3 , R^4 and R^5 are each independently selected from the group consisting of hydrogen, halo, CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{SO}_2\text{N}(\text{R}^{20})_2$, CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, C_{1-8} alkyl, C_{2-8} alkenyl, C_{2-8} alkynyl, heterocyclyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of
10 halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, or SO_2R^{22} ;

R^6 , R^7 and R^8 each independently selected from the group consisting of hydrogen or C_{1-3} alkyl;

R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , R^{15} and R^{16} are each independently selected from the group consisting of hydrogen, $\text{CON}(\text{R}^{20})_2$, C_{1-4} alkyl, or aryl wherein the alkyl and aryl substituents
15 are each optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , OR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{CON}(\text{R}^{20})_2$ or aryl wherein R^9 and R^{10} may together form a carbonyl, or R^{11} and R^{12} may together form a carbonyl, or R^{13} and R^{14} may together form a carbonyl, or R^{15} and R^{16} may together form a carbonyl with the proviso that R^{11} and R^{13} or R^9 and R^{15} or R^9 and R^{11} or R^{11} and R^{15} or R^9 and R^{13} may join together to form a ring;

20 R^{17} is a 5 or 6-membered ring containing from 1 to 3 heteroatoms selected from the group consisting of N, S, or O that is optionally substituted with from 1 to 3 substituents selected from the group consisting of hydrogen, halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, SO_2R^{22} , $\text{SO}_2\text{N}(\text{R}^{20})_2$, $\text{NR}^{20}\text{CO}_2\text{R}^{22}$, $\text{NR}^{20}\text{CON}(\text{R}^{20})_2$, COR^{20} , CO_2R^{20} , $\text{CON}(\text{R}^{20})_2$, $\text{NR}^{20}\text{SO}_2\text{R}^{22}$, C_{1-15} alkyl, C_{2-15} alkenyl, C_{2-15} alkynyl, heterocyclyl, aryl, or heteroaryl,
25 wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, NO_2 , CF_3 , CN , OR^{20} , SR^{20} , $\text{N}(\text{R}^{20})_2$, $\text{S}(\text{O})\text{R}^{22}$, or SO_2R^{22} .

R^{20} is selected from the group consisting of H, C_{1-15} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the
30 group consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl-CN, $-\text{O}-\text{C}_{1-6}$ alkyl, or CF_3 ; and

R^{22} is selected from the group consisting of C_{1-15} alkyl, aryl, or heteroaryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group

consisting of halo, alkyl, monoalkylamino, dialkylamino, alkyl amide, aryl amide, heteroaryl amide, CN, O-C₁₋₆ alkyl, CF₃, or heteroaryl.

29. The compound of claim 27 wherein q = O;

R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of
5 hydrogen, halo, CF₃, OR²⁰, C₁₋₅ alkyl, C₂₋₅ alkenyl, or C₂₋₅ alkynyl, wherein the alkyl substituent is optionally substituted with CF₃;

R⁶, R⁷ and R⁸ each independently selected from the group consisting of hydrogen or C₁₋₃ alkyl;

R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶ are each independently selected from the group
10 consisting of hydrogen, CON(R²⁰)₂, C₁₋₃ alkyl, or aryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, N(R²⁰)₂, and aryl or wherein R⁹ and R¹⁰ may together form a carbonyl, or R¹¹ and R¹² may together form a carbonyl with the proviso that R¹¹ and R¹³ or R⁹ and R¹⁵ or R⁹ and R¹¹ or R¹¹ and R¹⁵ or R⁹ and R¹³ may join together to form a ring;

15 R¹⁷ is a 5 or 6 membered ring including from 1 to 3 heteroatoms selected from N, S, or O nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF₃,
20 OR²⁰, or N(R²⁰)₂; and

R²⁰ is selected from the group consisting of H, C₁₋₈ alkyl, aryl, or heteroaryl wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, -O-C₁₋₃ alkyl, or CF₃.

30. The compound of claim 29 wherein R¹⁷ is a 6 membered ring including from 1
25 to 2 nitrogen atoms that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF₃, OR²⁰, N(R²⁰)₂, CON(R²⁰)₂, C₁₋₈ alkyl, C₂₋₈ alkenyl, C₂₋₈ alkynyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent independently selected from the group consisting of halo, CF₃, OR²⁰, or N(R²⁰)₂.

30 31. The compound of claim 30 wherein q = O;

R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen, OR²⁰, or methyl;

R⁶, R⁷ and R⁸ are each hydrogen;

$R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}$ and R^{16} are each independently selected from the group consisting of hydrogen, C_{1-2} alkyl, or R^9 and R^{10} may together form a carbonyl;

R^{17} is a 6 membered ring containing from 1 to 2 nitrogen atoms that is optionally substituted with methyl; and

5 R^{20} is H.

32. The compound of claim 30 wherein $q = O$;

R^1, R^2, R^3, R^4 and R^5 are each independently selected from the group consisting of hydrogen or methyl;

R^6, R^7 and R^8 are each hydrogen;

10 $R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}$ and R^{16} are each hydrogen; and

R^{17} is a 6 membered ring containing 1 nitrogen atom that is optionally substituted with methyl.

33. The composition of claim 10 wherein $q = NH$; and

15 R^{17} is a heteroaryl that is a fused 6,5 system containing from 1 to 2 heteroatoms selected from the group consisting of N, O, or S that is optionally substituted with from 1 to 2 substituents selected from the group consisting of hydrogen, halo, CF_3 , OR^{20} , $N(R^{20})_2$, $CON(R^{20})_2$, C_{1-3} alkyl, aryl, or heteroaryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo, CF_3 , OR^{20} , or $N(R^{20})_2$;

20 34. The composition of claim 10 wherein $q = NH$;

R^1, R^2, R^3, R^4 and R^5 are each independently selected from the group consisting of hydrogen, CF_3 , OR^{20} , or C_{1-2} alkyl;

R^6, R^7 and R^8 are each hydrogen;

25 $R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^{15}$ and R^{16} are each independently selected from the group consisting of hydrogen or C_{1-2} alkyl, or wherein R^9 and R^{10} may together form a carbonyl;

R^{17} is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of benzothiazole, and benzoxazole that is optionally substituted with 1 substituent selected from the group consisting of hydrogen, CF_3 , OR^{20} , C_{1-3} alkyl, or aryl, wherein the alkyl and aryl substituents are optionally substituted with 1 substituent selected from the group consisting of halo or CF_3 ; and

30 R^{20} is selected from the group consisting of H or C_{1-3} alkyl.

35. The composition of claim 10 wherein q = NH;

R¹, R², R³, R⁴ and R⁵ are each independently selected from the group consisting of hydrogen or methyl;

R⁶, R⁷ and R⁸ are each hydrogen;

5 R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, R¹⁵ and R¹⁶ are each hydrogen; and

R¹⁷ is a heteroaryl that is a fused 6,5 membered ring system selected from the group consisting of benzothiazole, and benzoxazole that is optionally substituted with methyl.

36. A compound selected from the group consisting of N-(2,6-dimethyl-phenyl)-2-(4-{2-hydroxy-3-[2-(3-trifluoromethylphenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, 2-{4-[3-(benzothiazol-2-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethylphenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, 4-(3-{4-[(2,6-dimethylphenylcarbamoyl)-methyl]-piperazin-1-yl}-2-hydroxy-propoxy)-1H-indole-2-carboxylic acid amide, 2-{4-[3-(benzothiazol-6-yloxy)-2-hydroxy-propyl]-piperazin-1-yl}-N-(2,6-dimethyl-phenyl)-acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-3,5-dimethyl-piperazine-1-yl}acetamide, 2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}-N-(4-hydroxy-phenyl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-phenyl-benzothiazol-7-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzothiazol-5-yloxy)-propyl]-2-oxo-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-benzoxazol-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-(4-{2-hydroxy-3-[2-(4-trifluoromethyl-phenyl)-benzoxazol-5-yloxy]-propyl}-piperazin-1-yl)acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinoxalin-2-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(pyridin-3-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-4-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(isoquinolin-5-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(quinolin-6-yloxy)-propyl]-piperazin-1-yl}acetamide, N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methyl-quinolin-7-yloxy)-propyl]-piperazin-1-yl}acetamide, 2-{4-[3-(benzothiazol-2-

ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[3-(benzoxazol-2-ylamino)-2-hydroxypropyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,5-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3,3-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{(2R)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl](1,4-diazaperhydroepinyl)}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-hydroxyphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,6-dimethylpiperazinyl}-N-(4-carboxamidophenyl)acetamide, 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2R)-2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethyl-4-hydroxyphenyl)acetamide, 2-{5-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]-2,5-diazabicyclo[2.2.1]hept-2-yl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(4-sulfamoylphenyl)acetamide, 2-{(3S)-4-[(2S)-2-hydroxy-3-(2-phenylbenzoxazol-5-yloxy)propyl]-3-methylpiperazinyl}-N-(2,6-dimethylphenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-naphthylacetamide, N-[4-chloro-3-(trifluoromethyl)phenyl]-2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-phenylacetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide, 2-{4-[2-hydroxy-3-(4-methoxyphenyl)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-

yloxy)propyl]piperazinyl-N-(2-chloro-4-methylphenyl)-acetamide, 2-{4-[2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4,5-trichlorophenyl)acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,5-dichlorophenyl)-acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(3,4-dichlorophenyl)-acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[3-methoxy-5-(trifluoromethyl)phenyl]acetamide, 2-{4-[2-hydroxy-3-(2-phenylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-[3,5-dichlorophenyl]acetamide, and 2-{4-[2-hydroxy-3-(2-((1E)buta-1,3-dienyl)benzothiazol-5-yloxy)propyl]piperazinyl}-N-[4-chloro-2-methoxy-5-methylphenyl]acetamide.

10 37. A method of treatment comprising administering a therapeutically effective amount of a compound of claim 1 to a mammal in need of a treatment selected from the group consisting of protecting skeletal muscles against damage resulting from trauma, protecting skeletal muscles subsequent to muscle or systemic diseases, treating shock conditions, preserving donor tissue and organs used in transplants, or treating cardiovascular
15 diseases.

38. The method of claim 37 wherein the cardiovascular disease is selected from the group consisting of atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, exercise induced angina, congestive heart disease, or myocardial infarction.

39. The method of claim 37 or 38 wherein the therapeutically effective amount
20 ranges from about 0.01 to about 100 mg/kg weight of the mammal.

40. The method of claim 37 or 38 wherein the mammal is a human.

41. A pharmaceutical composition of matter comprising the composition of claim 1 and one or more pharmaceutical excipients.

42. The pharmaceutical composition of matter of claim 41 wherein the
25 pharmaceutical composition is in the form of a solution.

43. The pharmaceutical composition of matter of claim 41 wherein the pharmaceutical composition is in a form selected from the group consisting of a tablet or a capsule.

INTERNATIONAL SEARCH REPORT

International Application No.

PC1/US 01/51032

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D263/57 A61K31/496 C07D277/68 C07D209/42 C07D417/12
C07D241/44 C07D213/63 C07D215/20 A61P21/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 407 780 A (SYNTEX PHARMA LTD) 16 January 1991 (1991-01-16) page 1, line 23 - line 50 page 2, line 11 - line 25	1-43
A	MCCORMACK J G ET AL: "RANOLAZINE: A NOVEL METABOLIC MODULATOR FOR THE TREATMENT OF ANGINA" GENERAL PHARMACOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 30, no. 5, May 1998 (1998-05), pages 639-645, XP001058244 ISSN: 0306-3623 see paragraph: Mechanism of action of Ranolazine	1-43

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

2 July 2002

Date of mailing of the international search report

10/07/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5618 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Usueli, A

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 01/51032

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 01 62749 A (CV THERAPEUTICS INC ;ZABLOCKI JEFF (US); BLACKBURN BRENT (US); ELZ) 30 August 2001 (2001-08-30) page 2, line 5 -page 4, line 18; claim 1 -----	1-43

INTERNATIONAL SEARCH REPORT

ational application No.
PCT/US 01/51032

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 37-40 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Application No

PCT/US 01/51032

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0407780	A	16-01-1991	AT 142497 T	15-09-1996
			AT 218344 T	15-06-2002
			AU 633589 B2	04-02-1993
			AU 5761890 A	03-01-1991
			CA 2019580 A1	23-12-1990
			DE 69028457 D1	17-10-1996
			DK 407780 T3	30-09-1996
			EP 0407780 A2	16-01-1991
			EP 0714660 A1	05-06-1996
			EP 0719558 A1	03-07-1996
			ES 2091211 T3	01-11-1996
			GR 3020976 T3	31-12-1996
			IE 902250 A1	16-01-1991
			JP 3048672 A	01-03-1991
			JP 3232085 B2	26-11-2001
			NZ 234184 A	29-01-1997
			NZ 247044 A	24-04-1997
			US 5906988 A	25-05-1999
			US 5506229 A	09-04-1996
			ZA 9004842 A	26-02-1992
WO 0162749	A	30-08-2001	AU 3859001 A	03-09-2001
			WO 0162749 A1	30-08-2001
			US 2001044541 A1	22-11-2001